PATH Malaria Vaccine Initiative (MVI) Creates New Central "Reference" Lab, Standardizing Ability To Measure Performance Of Malaria Vaccine Formulations
MVI, International AIDS Vaccine Initiative, and Imperial College London Establish Collaboration to Guide Selection and Prioritization of Malaria Vaccine Candidates
WASHINGTON, Aug. 20, 2012 /PRNewswire-USNewswire/ -- In response to a critical gap in developing malaria vaccines, the PATH Malaria Vaccine Initiative (MVI) announced a new collaboration today with the International AIDS Vaccine Initiative (IAVI) and Imperial College London to measure the capacity of different vaccine candidates in human clinical testing to elicit an immune response aimed at protecting against deadly malaria parasites.
"Until now, malaria vaccine scientists have struggled to directly compare the cellular immune response elicited in humans by one vaccine to that of another, and this has hampered the ability to prioritize a portfolio of vaccine candidates," said David C. Kaslow, M.D., director of MVI. "We are fortunate to have in IAVI and Imperial College London partners with a track record of developing validated human immunological assays. Through this new collaboration, we look forward to being able to make better informed decisions about if and how various malaria vaccines elicit immune responses at the cellular level in humans."
One obstacle to comparing the cell-mediated immunity elicited by different malaria vaccine candidates has been the lack of uniform validated techniques and processes among the various laboratories used by MVI and its collaborators specifically to evaluate T-cell immunity. Previously, AIDS vaccine researchers faced similar challenges. In an effort to identify a more consistent understanding of how multiple vaccine candidates were performing at a cellular level, IAVI and its Human Immunology Laboratory (HIL) at Imperial College London refined and validated specific tests, or assays, that measure vaccine-induced, cell-mediated immunity. The HIL is accredited in Good Clinical Laboratory Practices (GCLP), an internationally recognized quality standard.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV